Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2012

NovAliX to Use Graffinity Screening Platform in Drug Discovery Deal with Teijin Pharma

  • NovAliX will use its Graffinity SPR-based screening platform in a drug discovery program of Teijin Pharma. NovAliX will use the technology to identify novel chemotypes, and then apply its native nano-MS technology to further characterize selected small molecule hit structures.

    Under the multitarget drug discovery collaboration, French-owned NovAliX said it will receive technology access fees as well as further research funding payments from the collaboration, its first with Teijin but its second with a Japanese pharmaceutical company.

    NovAliX-owned Graffinity Pharmaceuticals announced in March 2011 that it would apply the fragment based screening platform to a drug discovery program of Shionogi & Co., in return for unspecified technology access fees and payments.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »